|
Basic Characteristics of Mutations
|
|
Mutation Site
|
V353A |
|
Mutation Site Sentence
|
Marker transfer studies confirmed that the V353A and T409M mutations conferred ~15-fold and ~80-fold increases, respectively, in MBV resistance without significantly affecting ganciclovir susceptibility. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
UL97 |
|
Standardized Encoding Gene
|
UL97
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
AD169
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cytomegalovirus infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
MBV |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
17538888
|
|
Title
|
Cytomegalovirus UL97 kinase mutations that confer maribavir resistance
|
|
Author
|
Chou S,Wechel LC,Marousek GI
|
|
Journal
|
The Journal of infectious diseases
|
|
Journal Info
|
2007 Jul 1;196(1):91-4
|
|
Abstract
|
The cytomegalovirus (CMV) UL97 kinase inhibitor maribavir (MBV) is undergoing clinical antiviral trials. Two clinical CMV isolates serially passaged in cell culture under MBV showed >20-fold increases in MBV resistance after the development of the UL97 mutation V353A in one of the isolates and of T409M in the other. Marker transfer studies confirmed that the V353A and T409M mutations conferred ~15-fold and ~80-fold increases, respectively, in MBV resistance without significantly affecting ganciclovir susceptibility. The 3 UL97 mutations now known to confer MBV resistance are located upstream of UL97 mutations linked to ganciclovir resistance, closer to kinase domains that are associated with adenosine triphosphate binding and phosphotransfer.
|
|
Sequence Data
|
-
|